Literature DB >> 14614748

Establishment of ELISA on 384-well microplate for AFP, CEA, CA 19-9, CA 15-3, CA 125, and PSA-ACT: higher sensitivity and lower reagent cost.

Tsu-Lan Wu1, Yu-Chen Sun, Pi-Yueh Chang, Kuo-Chien Tsao, Chien-Feng Sun, James T Wu.   

Abstract

The 384-well microplate contains four times as many wells as the regular 96-well microplate. Establishing enzyme linked immunosorbent assay (ELISA) on 384-well microplate should lead to savings in reagents and specimens. To determine that ELISAs on 384-well microplate have acceptable assay precision, ELISAs for tumor markers, including AFP, PSA-ACT, CEA, CA 125, CA 15-3, and CA 19-9, were compared to the same ELISAs established on 96-well microplate. We found that ELISAs established on 384-well microplate had similar sensitivity and covered similar concentration ranges as ELISAs on 96-well microplate. All within-day and day-to-day precisions for the 384-ELISA had %CV less than 10%. Compared to ELISA on 96-well microplate, 384-ELISA used less reagents, less specimen, and exhibited approximately a two-fold increase in sensitivity. Overall cost of the 384-384-ELISA was also greatly reduced. Our results suggest that 384-ELISA is suitable for use in routine clinical laboratories. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614748      PMCID: PMC6807924          DOI: 10.1002/jcla.10104

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  2 in total

1.  A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein.

Authors:  Alexia Garrigues; Jérôme Nugier; Stéphane Orlowski; Eric Ezan
Journal:  Anal Biochem       Date:  2002-06-01       Impact factor: 3.365

2.  Functional screening of G protein-coupled receptors by measuring intracellular calcium with a fluorescence microplate reader.

Authors:  Matthias U Kassack; Barbara Höfgen; Jochen Lehmann; Niels Eckstein; J Mark Quillan; Wolfgang Sadée
Journal:  J Biomol Screen       Date:  2002-06
  2 in total
  2 in total

1.  Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel.

Authors:  Seong Beom Ahn; Samridhi Sharma; Abidali Mohamedali; Sadia Mahboob; William J Redmond; Dana Pascovici; Jemma X Wu; Thiri Zaw; Subash Adhikari; Vineet Vaibhav; Edouard C Nice; Mark S Baker
Journal:  Clin Proteomics       Date:  2019-08-28       Impact factor: 3.988

2.  Validation of Assaying Carcinoembryonic Antigen in Human Serum by Using Immunomagnetic Reduction.

Authors:  Po-Li Wei; Long-Teng Lee; Li-Ming Tseng; Kai-Wen Huang
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.